Evidence map›Paper›PMID 22407140›Full record

ArticleNeurosurgical review2012

Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies.

Georg Widhalm, Georgi Minchev, Adelheid Woehrer, Matthias Preusser, Barbara Kiesel, Julia Furtner, Aygül Mert, Antonio Di Ieva, Boguslaw Tomanek, Daniela Prayer and 4 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Neurosurgical review, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05850377 (5-Aminolevulinic Acid), which is not on this map. Cited by 43 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 4 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05850377 unknown statusnot on this mapstarted 2023, after this paper: background citation

5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

TypeobservationalSponsorSociedad de Lucha Contra el Cáncer del EcuadorRan2023 to 2026Enrolled90ConditionsHigh Grade Glioma, Glioma, Glioma, Malignant, Neoplasms, NeuroepithelialArms5-Aminolevulinic Acid (5-ALA) Gliolan®, Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Towards Optical Biopsy in Glioma Surgery.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Georg WidhalmDepartment of Neurosurgery, Medical University Vienna, Vienna, Austria.
Georgi Minchev
Adelheid Woehrer
Matthias Preusser
Barbara Kiesel
Julia Furtner
Aygül Mert
Antonio Di Ieva
Boguslaw Tomanek
Daniela Prayer
Christine Marosi
Johannes A Hainfellner
Engelbert Knosp
Stefan Wolfsberger
Medical University of Vienna · ATComprehensive Cancer Center Vienna · ATUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stereotactic biopsies represent a routine neurosurgical procedure for the diagnosis of intracranial lymphomas and selected diffusely infiltrating gliomas. Acquisition of tissue samples that do not allow correct tumor typing and grading is, however, not uncommon. Five-aminolevulinic acid (5-ALA) has been shown to accumulate in malignant tumor tissue. The aim of this study was to prospectively investigate the clinical usability of 5-ALA for intraoperative detection of representative tissue in stereotactic tumor biopsies. Fifty consecutive patients underwent frameless stereotactic biopsy for a suspected brain tumor. 5-ALA was administered 4 h before anesthesia. Serial biopsy samples were obtained and intraoperatively checked for 5-ALA fluorescence (strong, vague, or none) using a modified neurosurgical microscope. All samples were examined for the presence of representative tumor tissue according to neuroimaging (MRI, positron emission tomography, and/or chemical shift imaging) and histopathological parameters. Visible 5-ALA fluorescence was observed in 43/50 patients (strong in 39 and vague fluorescence in four cases). At biopsy target, 52/53 samples of glioblastomas, 9/10 samples of gliomas grade III, and 14/16 samples of lymphomas revealed strong 5-ALA fluorescence. Samples with strong 5-ALA fluorescence were only observed at, but not outside the biopsy target. All tissue samples with strong 5-ALA fluorescence were representative according to our neuroimaging and histopathological criteria (positive predictive value of 100%). Our data indicate that strong 5-ALA fluorescence is a reliable and immediately available intraoperative marker of representative tumor tissue of malignant gliomas and intracranial lymphomas in stereotactic biopsies. Thereby, the application of 5-ALA in stereotactic brain tumor biopsies may in future reduce costs for operating room and neuropathology and may decrease procedure-related morbidity.

Indexed as

Aminolevulinic AcidNeurosurgical ProceduresPhotosensitizing AgentsAdultAgedAged, 80 and overBiopsyBrain NeoplasmsFemaleFluorescenceGliomaHumansMagnetic Resonance ImagingMaleMiddle AgedNeuroimagingAminolevulinic AcidPhotosensitizing Agents

Identifiers

PMID22407140
OpenAlexW2034536646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.